Skip to main content
Erschienen in: Psychiatric Quarterly 1/2018

24.04.2017 | Original Paper

Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia

verfasst von: Huiqiong Deng, Ramandeep S. Kahlon, Satyajit Mohite, Pooja A. Amin, Giovana Zunta-Soares, Gabriela D. Colpo, Laura Stertz, Gabriel R. Fries, Consuelo Walss-Bass, Jair C. Soares, Olaoluwa O. Okusaga

Erschienen in: Psychiatric Quarterly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

S100B is a calcium binding protein mainly produced by glial cells. Previous studies have shown elevated levels of S100B in patients with schizophrenia. We measured S100B levels in fasting plasma of 39 patients with schizophrenia and 19 adult healthy controls. We used linear regression to compare S100B between patients and controls. In patients only, we also investigated the relationship between S100B levels and psychotic symptoms (assessed by the Positive and Negative Syndrome Scale), and cognitive function (assessed by the NIH Toolbox Cognition Battery), respectively by calculating Pearson’s correlation coefficients. Mean plasma S100B was significantly higher in the patient group than in the control group. There were no significant correlations between plasma S100B and psychotic symptoms or cognition.
Literatur
1.
Zurück zum Zitat Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19:739–744.CrossRefPubMed Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19:739–744.CrossRefPubMed
2.
Zurück zum Zitat Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21:134–140.CrossRefPubMed Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21:134–140.CrossRefPubMed
3.
Zurück zum Zitat Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2004; 29:1004–1011.CrossRef Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2004; 29:1004–1011.CrossRef
4.
Zurück zum Zitat Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60:540–551.CrossRefPubMed Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60:540–551.CrossRefPubMed
5.
Zurück zum Zitat Rothermundt M, Falkai P, Ponath G, Abel S, Burkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, Maier W, Schramm J, Suslow T, Ohrmann P, Arolt V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004; 9:897–899.CrossRefPubMed Rothermundt M, Falkai P, Ponath G, Abel S, Burkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, Maier W, Schramm J, Suslow T, Ohrmann P, Arolt V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004; 9:897–899.CrossRefPubMed
6.
Zurück zum Zitat Alexanian AR, Bamburg JR. Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB. FASEB J 1999; 13:1611–20.CrossRefPubMed Alexanian AR, Bamburg JR. Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB. FASEB J 1999; 13:1611–20.CrossRefPubMed
7.
Zurück zum Zitat Mariggió MA, Fulle S, Calissano P, Nicoletti I, Fanó G. The brain protein S-100ab induces apoptosis in PC12 cells. Neuroscience 1994; 60:29–35.CrossRefPubMed Mariggió MA, Fulle S, Calissano P, Nicoletti I, Fanó G. The brain protein S-100ab induces apoptosis in PC12 cells. Neuroscience 1994; 60:29–35.CrossRefPubMed
8.
Zurück zum Zitat Zhivotovsky B, Orrenius S, Brustugun OT, Døskeland SO. Injected cytochrome c induces apoptosis. Nature 1998; 391:449–450.CrossRefPubMed Zhivotovsky B, Orrenius S, Brustugun OT, Døskeland SO. Injected cytochrome c induces apoptosis. Nature 1998; 391:449–450.CrossRefPubMed
9.
Zurück zum Zitat Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LVC, Goncalves CA, Fonseca M, Hauck S, Souza DO. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 2001; 35:11–14.CrossRefPubMed Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LVC, Goncalves CA, Fonseca M, Hauck S, Souza DO. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 2001; 35:11–14.CrossRefPubMed
10.
Zurück zum Zitat Schmitt A, Bertsch T, Henning U, Tost H, Klimke A, Henn FA, Falkai P. Increased serum S100B in elderly, chronic schizophrenic patients: Negative correlation with deficit symptoms. Schizophr Res 2005; 80:305–313.CrossRefPubMed Schmitt A, Bertsch T, Henning U, Tost H, Klimke A, Henn FA, Falkai P. Increased serum S100B in elderly, chronic schizophrenic patients: Negative correlation with deficit symptoms. Schizophr Res 2005; 80:305–313.CrossRefPubMed
11.
Zurück zum Zitat Schroeter ML, Abdul-Khaliq H, Frühauf S, Höhne R, Schick G, Diefenbacher A, Blasig IE. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 2003; 62:231–236.CrossRefPubMed Schroeter ML, Abdul-Khaliq H, Frühauf S, Höhne R, Schick G, Diefenbacher A, Blasig IE. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 2003; 62:231–236.CrossRefPubMed
12.
Zurück zum Zitat Yelmo-Cruz S, Morera-Fumero AL, Abreu-González P. S100B and schizophrenia. Psychiatry Clin Neurosci 2013; 67:67–75.CrossRefPubMed Yelmo-Cruz S, Morera-Fumero AL, Abreu-González P. S100B and schizophrenia. Psychiatry Clin Neurosci 2013; 67:67–75.CrossRefPubMed
13.
Zurück zum Zitat Zhang XY, Xiu MH, Song C, Chen DC, Wu GY, Haile CN, Kosten TA, Kosten TR. Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res 2010; 44:1236–40.CrossRefPubMed Zhang XY, Xiu MH, Song C, Chen DC, Wu GY, Haile CN, Kosten TA, Kosten TR. Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res 2010; 44:1236–40.CrossRefPubMed
14.
Zurück zum Zitat Zhang XY, Xiu MH, Chen DC, Zhu FY, Wu GY, Haile CN, Lu L, Kosten TA, Kosten TR. Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. J Psychiatr Res 2010; 44:429–33.CrossRefPubMed Zhang XY, Xiu MH, Chen DC, Zhu FY, Wu GY, Haile CN, Lu L, Kosten TA, Kosten TR. Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. J Psychiatr Res 2010; 44:429–33.CrossRefPubMed
15.
Zurück zum Zitat Steiner J, Bielau H, Bernstein H-G, Bogerts B, Wunderlich MT. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006; 77:1284–1287.CrossRefPubMedPubMedCentral Steiner J, Bielau H, Bernstein H-G, Bogerts B, Wunderlich MT. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006; 77:1284–1287.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, Rudolf S, Wandinger KP, Kirchner H. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 2001; 6:445–9.CrossRefPubMed Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, Rudolf S, Wandinger KP, Kirchner H. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 2001; 6:445–9.CrossRefPubMed
17.
Zurück zum Zitat Ling S, Tang Y, Jiang F, Wiste A, Guo S, Weng Y, Yang T-S. Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. J Psychiatr Res 2007; 41:36–42.CrossRefPubMed Ling S, Tang Y, Jiang F, Wiste A, Guo S, Weng Y, Yang T-S. Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. J Psychiatr Res 2007; 41:36–42.CrossRefPubMed
18.
Zurück zum Zitat Hendouei N, Hamzeh S, Panahi A, Khazaeipour Z. Negative Correlation between Serum S100B and Leptin Levels in Schizophrenic Patients During Treatment with Clozapine and Risperidone : Preliminary Evidence. Iran J Pharm Res 2016; 15:323–330.PubMedPubMedCentral Hendouei N, Hamzeh S, Panahi A, Khazaeipour Z. Negative Correlation between Serum S100B and Leptin Levels in Schizophrenic Patients During Treatment with Clozapine and Risperidone : Preliminary Evidence. Iran J Pharm Res 2016; 15:323–330.PubMedPubMedCentral
19.
Zurück zum Zitat Qi LY, Xiu MH, Chen DC, Wang F, Kosten TA, Kosten TR, Zhang XY. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett 2009; 462:113–117.CrossRefPubMed Qi LY, Xiu MH, Chen DC, Wang F, Kosten TA, Kosten TR, Zhang XY. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett 2009; 462:113–117.CrossRefPubMed
20.
Zurück zum Zitat Roder JK, Roder JC, Gerlai R. Conspecific exploration in the T-maze: Abnormalities in S100β transgenic mice. Physiol Behav 1996; 60:31–36.CrossRefPubMed Roder JK, Roder JC, Gerlai R. Conspecific exploration in the T-maze: Abnormalities in S100β transgenic mice. Physiol Behav 1996; 60:31–36.CrossRefPubMed
21.
Zurück zum Zitat Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC. Transgenic mice overexpressing the neurotrophic factor S-100β show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer’s disease and Down’s syndrome. Brain Res 1997; 776:51–60.CrossRefPubMed Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC. Transgenic mice overexpressing the neurotrophic factor S-100β show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer’s disease and Down’s syndrome. Brain Res 1997; 776:51–60.CrossRefPubMed
22.
Zurück zum Zitat Winocur G, Roder J, Lobaugh N. Learning and Memory in S100-β Transgenic Mice: An Analysis of Impaired and Preserved Function. Neurobiol Learn Mem 2001; 75:230–243.CrossRefPubMed Winocur G, Roder J, Lobaugh N. Learning and Memory in S100-β Transgenic Mice: An Analysis of Impaired and Preserved Function. Neurobiol Learn Mem 2001; 75:230–243.CrossRefPubMed
23.
Zurück zum Zitat Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, Ponath G, Kipp F, Abel S, Siegmund A, Suslow T, von Eiff C, Arolt V, Rothermundt M. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry 2008; 32:1789–1792.CrossRef Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, Ponath G, Kipp F, Abel S, Siegmund A, Suslow T, von Eiff C, Arolt V, Rothermundt M. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry 2008; 32:1789–1792.CrossRef
24.
Zurück zum Zitat Chen S, Tian L, Chen N, Xiu M, Wang Z, Yang G, Wang C, Yang F, Tan Y. Cognitive dysfunction correlates with elevated serum S100B concentration in drug-free acutely relapsed patients with schizophrenia. Psychiatry Res 2017; 247:6–11.CrossRefPubMed Chen S, Tian L, Chen N, Xiu M, Wang Z, Yang G, Wang C, Yang F, Tan Y. Cognitive dysfunction correlates with elevated serum S100B concentration in drug-free acutely relapsed patients with schizophrenia. Psychiatry Res 2017; 247:6–11.CrossRefPubMed
25.
Zurück zum Zitat Sheehan D V, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M, Lecrubier Y, Weiller E, Hergueta T, Amorim P, others. MINI-Mini International neuropsychiatric interview-english version 5.0. 0-DSM-IV. J Clin Psychiatry 1998; 59:34–57. Sheehan D V, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M, Lecrubier Y, Weiller E, Hergueta T, Amorim P, others. MINI-Mini International neuropsychiatric interview-english version 5.0. 0-DSM-IV. J Clin Psychiatry 1998; 59:34–57.
26.
Zurück zum Zitat Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261.CrossRefPubMed Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261.CrossRefPubMed
27.
Zurück zum Zitat Gershon RC, Wagster M V, Hendrie HC, Fox NA, Cook KF, Nowinski CJ. NIH toolbox for assessment of neurological and behavioral function. Neurology 2013; 80:S2--S6.CrossRefPubMedPubMedCentral Gershon RC, Wagster M V, Hendrie HC, Fox NA, Cook KF, Nowinski CJ. NIH toolbox for assessment of neurological and behavioral function. Neurology 2013; 80:S2--S6.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Zelazo PD, Bauer PJ. National institutes of health toolbox cognition battery (NIH Toolbox CB): Validation for children between 3 and 15 years. Wiley; 2013. Zelazo PD, Bauer PJ. National institutes of health toolbox cognition battery (NIH Toolbox CB): Validation for children between 3 and 15 years. Wiley; 2013.
29.
Zurück zum Zitat Steiner J, Bernstein H-G, Bielau H, Farkas N, Winter J, Dobrowolny H, Brisch R, Gos T, Mawrin C, Myint AM. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 2008; 42:868–876.CrossRefPubMed Steiner J, Bernstein H-G, Bielau H, Farkas N, Winter J, Dobrowolny H, Brisch R, Gos T, Mawrin C, Myint AM. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 2008; 42:868–876.CrossRefPubMed
30.
Zurück zum Zitat Morera-Fumero AL, Díaz-Mesa E, Abreu-Gonzalez P, Fernandez-Lopez L, Cejas-Mendez M del R. Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry 2017; 75:207–212. Morera-Fumero AL, Díaz-Mesa E, Abreu-Gonzalez P, Fernandez-Lopez L, Cejas-Mendez M del R. Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry 2017; 75:207–212.
31.
Zurück zum Zitat Steiner J, Bernstein H-G, Bielau H, Berndt A, Brisch R, Mawrin C, Keilhoff G, Bogerts B. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007; 8:2.CrossRefPubMedPubMedCentral Steiner J, Bernstein H-G, Bielau H, Berndt A, Brisch R, Mawrin C, Keilhoff G, Bogerts B. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007; 8:2.CrossRefPubMedPubMedCentral
Metadaten
Titel
Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia
verfasst von
Huiqiong Deng
Ramandeep S. Kahlon
Satyajit Mohite
Pooja A. Amin
Giovana Zunta-Soares
Gabriela D. Colpo
Laura Stertz
Gabriel R. Fries
Consuelo Walss-Bass
Jair C. Soares
Olaoluwa O. Okusaga
Publikationsdatum
24.04.2017
Verlag
Springer US
Erschienen in
Psychiatric Quarterly / Ausgabe 1/2018
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-017-9514-y

Weitere Artikel der Ausgabe 1/2018

Psychiatric Quarterly 1/2018 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.